BRWA
NTLA icon

B. Riley Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

B. Riley Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$3.45K – 1125
2025
Q3 		$3.45K Buy
+200
New +$2.46K ﹤0.01% 1067
2022
Q1 		– Sell
-2,631
Closed -$312K – 1464
2021
Q4 		$312K Sell
2,631
-431
-14% -$54K 0.01% 1047
2021
Q3 		$423K Sell
3,062
-373
-11% -$56.5K 0.01% 865
2021
Q2 		$557K Buy
3,435
+578
+20% +$45K 0.02% 718
2021
Q1 		$230K Buy
+2,857
New +$192K 0.01% 1130

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

B. Riley Wealth Advisors's NTLA Position: Q4 2025 in Review

B. Riley Wealth Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 200 shares — an estimated $3.45K sold.

B. Riley Wealth Advisors first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $557K in Q2 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • B. Riley Wealth Advisors reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 200 Intellia Therapeutics shares in Q4 2025, an estimated $3.45K.
  • B. Riley Wealth Advisors first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
  • B. Riley Wealth Advisors's Intellia Therapeutics position peaked at $557K in Q2 2021.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.